This study investigates formulations of vortioxetine applied under the tongue

Apart from the first two doses, the study design is flexible in terms of doses and pharmaceutical formulations and will be decided upon based on an evaluation of the safety and tolerability as well as plasma exposure obtained during the study.

• The study consists of 5 periods. Single-doses of vortioxetine will be administered in all periods.

• All subjects will receive the same pharmaceutical formulations of the same dose strength in the same period and sequence.

• In Period 1, each subject will receive an intravenous (IV) 10 mg dose of vortioxetine infused over 2 hours. The exposure obtained after IV administration will serve as the reference for the sublingually administered dosage forms.

• In Period 2, each subject will receive 5 mg of formulation A (SLA) of vortioxetine in a sublingual (SL) formulation with a holding time of 90 seconds. The holding time is the time where swallowing of saliva should be avoided.

• For the 3 remaining dosing periods, one or more of the following options in pharmaceutical formulation, dose, and dosing condition apply to this study:

  • Increases or decreases in dose (≤25mg) using same formulation
  • Change from formulation SLA to formulation SLB
  • Change in the holding time
  • Change to formulation SLC
  • Change in swallowing technique of the sublingual dosage forms

Inclusion Criteria:

-The subject has a BMI ≥18.5 and ≤30.0 kg/m2 at the Screening Visit and at the Baseline Visit.

Exclusion Criteria:

-The subject is identified or confirmed to be a CYP2D6 poor metabolizer (PM)